These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 12212779)
1. The utility of muscarinic agonists in the treatment of Alzheimer's disease. Messer WS J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779 [TBL] [Abstract][Full Text] [Related]
2. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950 [TBL] [Abstract][Full Text] [Related]
3. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772 [TBL] [Abstract][Full Text] [Related]
4. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. Forlenza OV; Spink JM; Dayanandan R; Anderton BH; Olesen OF; Lovestone S J Neural Transm (Vienna); 2000; 107(10):1201-12. PubMed ID: 11129110 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists. Messer WS; Abuh YF; Liu Y; Periyasamy S; Ngur DO; Edgar MA; El-Assadi AA; Sbeih S; Dunbar PG; Roknich S; Rho T; Fang Z; Ojo B; Zhang H; Huzl JJ; Nagy PI J Med Chem; 1997 Apr; 40(8):1230-46. PubMed ID: 9111297 [TBL] [Abstract][Full Text] [Related]
7. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy. Verma S; Kumar A; Tripathi T; Kumar A J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387 [TBL] [Abstract][Full Text] [Related]
8. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells. DeLapp N; Wu S; Belagaje R; Johnstone E; Little S; Shannon H; Bymaster F; Calligaro D; Mitch C; Whitesitt C; Ward J; Sheardown M; Fink-Jensen A; Jeppesen L; Thomsen C; Sauerberg P Biochem Biophys Res Commun; 1998 Mar; 244(1):156-60. PubMed ID: 9514902 [TBL] [Abstract][Full Text] [Related]
9. Novel persistent activation of muscarinic M1 receptors by xanomeline. Christopoulos A; El-Fakahany EE Eur J Pharmacol; 1997 Sep; 334(1):R3-4. PubMed ID: 9346340 [TBL] [Abstract][Full Text] [Related]
10. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Flynn DD; Weinstein DA; Mash DC Ann Neurol; 1991 Mar; 29(3):256-62. PubMed ID: 2042942 [TBL] [Abstract][Full Text] [Related]
11. Muscarinic M(1) agonists in the treatment of Alzheimer's disease. Korczyn AD Expert Opin Investig Drugs; 2000 Oct; 9(10):2259-67. PubMed ID: 11060805 [TBL] [Abstract][Full Text] [Related]
12. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170 [TBL] [Abstract][Full Text] [Related]
13. Cholinergic agonists and the treatment of Alzheimer's disease. Messer WS Curr Top Med Chem; 2002 Apr; 2(4):353-8. PubMed ID: 11966459 [TBL] [Abstract][Full Text] [Related]
14. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Clader JW; Wang Y Curr Pharm Des; 2005; 11(26):3353-61. PubMed ID: 16250841 [TBL] [Abstract][Full Text] [Related]